Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 0.79 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164884 | 0.88 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20164886 | 0.88 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20164820 | 0.87 | AAK1 (1.00) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20164819 | 0.87 | AAK1 (1.00) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20164851 | 0.86 | AAK1 (1.00) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20164850 | 0.86 | AAK1 (1.00) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20164830 | 0.86 | AAK1 (0.88) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20164831 | 0.86 | AAK1 (0.88) | AAK1CITMKNK1BMP2K | |
| SCHEMBL20181512 | 0.84 | AAK1 (0.78) | AAK1 | |
| SCHEMBL21019441 | 0.81 | AAK1 (0.61) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | AAK1 1/4885CIT 969/4885MKNK1 59/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885CIT 969/4885MKNK1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.